FDA approves generic versions of Imitrex

Jerusalem The Food and Drug Administration has approved Teva Pharmaceutical Industries’ generic version of GlaxoSmithKline’s Imitrex, Teva announced Wednesday.

Teva’s sumatriptan tablets will be available in 25-mg, 50-mg and 100-mg strengths, and have already begun to ship.

Sumatriptan is used to treat acute migraine attacks. The drug had sales of about $1 billion for the 12 months ending in December, according to IMS Health.

The FDA also approved Indian generic drug maker Ranbaxy’s version in the 100-mg strength and injected forms of sumatriptan from Teva and Wockhardt.